Refreshed weekly · May 2026

Biotech catalysts,
vetted by AI.

Specialist-persona models rate every upcoming readout. Smart-money positioning cross-checks the verdict. One weekly newsletter cuts to the asymmetric setups.

What's inside

Catalysts, capital, and the deep read.

One foundation — specialist-persona AI — across a catalyst calendar, a per-ticker research workflow, and a smart-money tracker.

Catalysts

Verdicts from specialists who actually read trials.

Each catalyst is routed to the specialist most likely to spot the asymmetry — the way a buyside biotech team triages a readout.

Oncology Neurology Cardiometabolic Pulmonology Immunology Rare disease
Smart money

Where the specialists are quietly building.

We track specialist biotech funds quarter over quarter. When accumulation pattern shifts on a name, the signal surfaces on the page.

Ticker research

The full read, one ticker at a time.

Type a ticker and get the structured workup — pipeline, science, financials, market positioning, management, sentiment, and a recommendation. Per-ticker news feed and chart links included.

Pipeline Science Financials Market Management Sentiment Recommendation
This month

A few of the top catalysts.

Pulled live from the table. Updated weekly.

Loading top catalysts…
See the full table
Pricing

Pick your access tier.

Both tiers start with a 7-day free trial. Cancel anytime.

Reader
$19 /month

Stay current on every catalyst and where the specialist funds are quietly building.

  • Full catalyst table, refreshed weekly
  • Smart-money tracker
Start 7-day trial